{"protocolSection": {"identificationModule": {"nctId": "NCT02768298", "orgStudyIdInfo": {"id": "CLCZ696BDE01"}, "secondaryIdInfos": [{"id": "2015-004632-35", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.", "officialTitle": "A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)."}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-07-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-11-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-11-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-05-09", "studyFirstSubmitQcDate": "2016-05-09", "studyFirstPostDateStruct": {"date": "2016-05-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-09-16", "resultsFirstSubmitQcDate": "2020-09-16", "resultsFirstPostDateStruct": {"date": "2020-10-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-07", "lastUpdatePostDateStruct": {"date": "2021-10-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.", "detailedDescription": "This study was a randomized, double-blind, double-dummy, parallel-group, active-controlled, two-arm trial to compare LCZ696 200 mg twice daily (bid) to enalapril 10 mg bid in improving exercise capacity, daily physical activity and quality of life in patients with stable chronic heart failure (New York Heart Association III) and reduced left ventricular ejection fraction (LVEF \u2264 40%).\n\nThe study consisted of a screening period of 2 weeks during which the subject's eligibility for the study was assessed followed by a double blind treatment period of 12 weeks. Eligible subjects were randomized 1:1 to receive either LCZ696 or enalapril during the double-blind period. Treatment was initiated with LCZ696 100 mg bid or enalapril 5 mg bid (enalapril 10 mg bid for patients at a stable daily dose of enalapril above 10 mg per day or corresponding doses of other angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) prior first screening visit), respectively. Dose was up-titrated after 2 weeks to the final dose of LCZ696 200 mg bid or enalapril 10 mg bid.\n\nPatients continued to take their background medications for chronic heart failure during the study, with the exception of ACEI or ARBs which were replaced by investigational treatment and had to be discontinued before first dose of study drug.\n\nThe primary objective was to demonstrate the superiority of LCZ696 200 mg bid compared to enalapril 10 mg bid in improving exercise tolerance (peak respiratory oxygen uptake (VO2peak), adjusted to body weight) as assessed by cardio-pulmonary-exercise testing (CPET) in patients with stable chronic heart failure (NYHA III) and reduced ejection fraction (LVEF \u2264 40%) after 3 months treatment."}, "conditionsModule": {"conditions": ["Chronic Heart Failure With Reduced Ejection Fraction"], "keywords": ["LCZ696", "sacubitril/valsartan", "VO2peak", "heart failure", "systolic heart failure", "heart failure with reduced ejection fraction", "exercise capacity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 201, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696", "type": "EXPERIMENTAL", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.", "interventionNames": ["Drug: LCZ696", "Drug: Placebo matching enalapril"]}, {"label": "Enalapril", "type": "ACTIVE_COMPARATOR", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.", "interventionNames": ["Drug: Enalapril", "Drug: Placebo matching LCZ696"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.", "armGroupLabels": ["LCZ696"]}, {"type": "DRUG", "name": "Enalapril", "description": "Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.", "armGroupLabels": ["Enalapril"]}, {"type": "DRUG", "name": "Placebo matching enalapril", "description": "Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.", "armGroupLabels": ["LCZ696"]}, {"type": "DRUG", "name": "Placebo matching LCZ696", "description": "Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.", "armGroupLabels": ["Enalapril"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of Treatment", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. One of the parameters attained by this test is the peak respiratory oxygen uptake (VO2peak).\n\nCPET to assess VO2peak was performed at a cycle ergometer at baseline (Visit 2, 9 days prior randomization) and after 6 weeks and 3 months of treatment (Visit 6 and Visit 7, respectively).\n\nThe VO2peak adjusted to body weight was calculated based on the corresponding visit's VO2peak (unadjusted) and body weight data by using the following formula: VO2peak (unadjusted)/body weight.\n\nHigher values of VO2peak indicate less symptom severity and therefore a positive change from baseline indicates improvement.", "timeFrame": "Baseline, 3 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 6 Weeks of Treatment", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. One of the parameters attained by this test is the peak respiratory oxygen uptake (VO2peak).\n\nCPET to assess VO2peak was performed at a cycle ergometer at baseline (Visit 2, 9 days prior randomization) and after 6 weeks and 3 months of treatment (Visit 6 and Visit 7, respectively).\n\nThe VO2peak adjusted to body weight was calculated based on the corresponding visit's VO2peak (unadjusted) and body weight data by using the following formula: VO2peak (unadjusted)/body weight.\n\nA positive change from baseline indicates less symptom severity.", "timeFrame": "Baseline, 6 weeks"}, {"measure": "Change From Baseline in the Minute Ventilation (VE) to Carbon Dioxide Output Slope (VE/VCO2 Slope)", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. One of the parameters attained by this test is the minute ventilation (VE) to carbon dioxide output slope (VE/VCO2 slope). High values of VE/VCO2 slope resembles the inability to eliminate CO2 by respiration (inefficient ventilation).\n\nA negative change from baseline indicates less symptom severity.", "timeFrame": "Baseline, 6 weeks, 3 months"}, {"measure": "Change From Baseline in Exercise Capacity (Watt) at Ventilatory Anaerobic Threshold (VAT)", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. CPET was performed at a cycle ergometer with a workload that started at 10 watts (W) and then increased by 10W for each 1-minute stage.\n\nExercise capacity assessed as workload in watts was determined at the ventilatory anaerobic threshold (VAT) which represents the transition from aerobic to partially anaerobic glucose metabolism in muscle, leading to increasing carbon dioxide exhalation in comparison to oxygen uptake.\n\nA positive change from baseline in exercise capacity (watt) indicates improvement.", "timeFrame": "Baseline, 6 weeks, 3 months"}, {"measure": "Change From Baseline in Rate of Perceived Exertion (Perceived Dyspnea and Perceived Fatigue) During Exercise Assessed by Borg Scale", "description": "The individually perceived exertion, in terms of perceived dyspnea and perceived fatigue, during cardiopulmonary exercise testing (CPET) was assessed by Borg scale which is a 15 point scale, starting from 6 which indicates \"No exertion at all\" to 20 which means \"Maximal exertion\".\n\nChange in Borg scale for both perceived dyspnea and perceived fatigue were measured at different time points at Baseline (Visit 2, 9 days prior randomization) and 3 months of treatment (Visit 7). Maximum value among the time points at every visit was used for the analysis.\n\nA negative change from baseline in Borg value of perceived dyspnea and perceived fatigue indicates improvement.", "timeFrame": "Baseline, 3 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a diagnosis of chronic heart failure (NYHA class III) and reduced ejection fraction (LVEF \u2264 40%)\n* Reduced ability to exercise, evidenced by VO2peak \u2264 18 ml/min per kg\n* Patients had to be on an ACEI or an ARB at a stable dose of at least enalapril 10 mg/d or equivalent for at least 4 weeks prior to the screening visit and until randomization visit.\n\nExclusion Criteria:\n\n* History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drugs\n* Previous history of intolerance to recommended target doses of ACEIs or ARBs\n* Known history of angioedema\n* Requirement of treatment with both ACEIs and ARBs\n* Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)\n* Symptomatic hypotension\n* Impaired renal function\n* Pregnant or nursing (lactating) women", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Regensburg", "state": "Bavaria", "zip": "93053", "country": "Germany", "geoPoint": {"lat": 49.01513, "lon": 12.10161}}, {"facility": "Novartis Investigative Site", "city": "Dresden", "state": "Sachsen", "zip": "01099", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13055", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13405", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Bonn", "zip": "53115", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "Novartis Investigative Site", "city": "Dresden", "zip": "01277", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novartis Investigative Site", "city": "Dresden", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novartis Investigative Site", "city": "Erfurt", "zip": "99089", "country": "Germany", "geoPoint": {"lat": 50.9787, "lon": 11.03283}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Freiburg", "zip": "79106", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Novartis Investigative Site", "city": "Gottingen", "zip": "37075", "country": "Germany", "geoPoint": {"lat": 51.53443, "lon": 9.93228}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "22291", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Heidelberg", "zip": "69115", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"facility": "Novartis Investigative Site", "city": "Kiel", "zip": "24105", "country": "Germany", "geoPoint": {"lat": 54.32133, "lon": 10.13489}}, {"facility": "Novartis Investigative Site", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Novartis Investigative Site", "city": "Koeln-Nippes", "zip": "50733", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"facility": "Novartis Investigative Site", "city": "Koeln", "zip": "50937", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"facility": "Novartis Investigative Site", "city": "Koeln", "zip": "51065", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"facility": "Novartis Investigative Site", "city": "Leverkusen", "zip": "51375", "country": "Germany", "geoPoint": {"lat": 51.0303, "lon": 6.98432}}, {"facility": "Novartis Investigative Site", "city": "Ludwigsburg", "zip": "71634", "country": "Germany", "geoPoint": {"lat": 48.89731, "lon": 9.19161}}, {"facility": "Novartis Investigative Site", "city": "Ludwigshafen", "zip": "67063", "country": "Germany", "geoPoint": {"lat": 49.48121, "lon": 8.44641}}, {"facility": "Novartis Investigative Site", "city": "Muenchen", "zip": "81675", "country": "Germany", "geoPoint": {"lat": 51.60698, "lon": 13.31243}}, {"facility": "Novartis Investigative Site", "city": "Neuwied", "zip": "56564", "country": "Germany", "geoPoint": {"lat": 50.4336, "lon": 7.47057}}, {"facility": "Novartis Investigative Site", "city": "Nienburg", "zip": "31582", "country": "Germany", "geoPoint": {"lat": 52.6461, "lon": 9.22086}}, {"facility": "Novartis Investigative Site", "city": "Rotenburg an der Fulda", "zip": "36199", "country": "Germany", "geoPoint": {"lat": 50.99556, "lon": 9.72838}}, {"facility": "Novartis Investigative Site", "city": "R\u00fcdersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Novartis Investigative Site", "city": "Siegen", "zip": "57072", "country": "Germany", "geoPoint": {"lat": 50.87481, "lon": 8.02431}}, {"facility": "Novartis Investigative Site", "city": "Ulm", "zip": "89077", "country": "Germany", "geoPoint": {"lat": 48.39841, "lon": 9.99155}}, {"facility": "Novartis Investigative Site", "city": "Villingen-Schwenningen", "zip": "78052", "country": "Germany", "geoPoint": {"lat": 48.06226, "lon": 8.49358}}, {"facility": "Novartis Investigative Site", "city": "Worms", "zip": "67550", "country": "Germany", "geoPoint": {"lat": 49.63278, "lon": 8.35916}}, {"facility": "Novartis Investigative Site", "city": "Wuerzburg", "zip": "97080", "country": "Germany", "geoPoint": {"lat": 49.79391, "lon": 9.95121}}, {"facility": "Novartis Investigative Site", "city": "Wuppertal", "zip": "42117", "country": "Germany", "geoPoint": {"lat": 51.27027, "lon": 7.16755}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicaltrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=647"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were randomized 1:1 to receive either LCZ696 or enalapril during the double-blind period.", "recruitmentDetails": "Participants took part in 34 investigative sites in Germany.", "groups": [{"id": "FG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "FG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "103"}, {"groupId": "FG001", "numSubjects": "98"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}, {"groupId": "FG001", "numSubjects": "91"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Subject/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal of informed consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "BG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "103"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "201"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.1", "spread": "10.792"}, {"groupId": "BG001", "value": "67.6", "spread": "9.961"}, {"groupId": "BG002", "value": "66.9", "spread": "10.396"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "38"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "163"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Caucassian", "measurements": [{"groupId": "BG000", "value": "101"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "197"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of Treatment", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. One of the parameters attained by this test is the peak respiratory oxygen uptake (VO2peak).\n\nCPET to assess VO2peak was performed at a cycle ergometer at baseline (Visit 2, 9 days prior randomization) and after 6 weeks and 3 months of treatment (Visit 6 and Visit 7, respectively).\n\nThe VO2peak adjusted to body weight was calculated based on the corresponding visit's VO2peak (unadjusted) and body weight data by using the following formula: VO2peak (unadjusted)/body weight.\n\nHigher values of VO2peak indicate less symptom severity and therefore a positive change from baseline indicates improvement.", "populationDescription": "Full Analysis Set including patients with a valid measurements for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL/kg/min", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "OG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.51", "spread": "0.180"}, {"groupId": "OG001", "value": "0.19", "spread": "0.188"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.2327", "statisticalMethod": "ANCOVA", "paramType": "Least Squares (LS) Mean", "paramValue": "0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "0.85", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.268"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 6 Weeks of Treatment", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. One of the parameters attained by this test is the peak respiratory oxygen uptake (VO2peak).\n\nCPET to assess VO2peak was performed at a cycle ergometer at baseline (Visit 2, 9 days prior randomization) and after 6 weeks and 3 months of treatment (Visit 6 and Visit 7, respectively).\n\nThe VO2peak adjusted to body weight was calculated based on the corresponding visit's VO2peak (unadjusted) and body weight data by using the following formula: VO2peak (unadjusted)/body weight.\n\nA positive change from baseline indicates less symptom severity.", "populationDescription": "Full Analysis Set including patients with a valid measurements for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL/kg/min", "timeFrame": "Baseline, 6 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "OG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.28", "spread": "0.185"}, {"groupId": "OG001", "value": "0.42", "spread": "0.195"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6247", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "-0.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.68", "ciUpperLimit": "0.41", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.277"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Minute Ventilation (VE) to Carbon Dioxide Output Slope (VE/VCO2 Slope)", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. One of the parameters attained by this test is the minute ventilation (VE) to carbon dioxide output slope (VE/VCO2 slope). High values of VE/VCO2 slope resembles the inability to eliminate CO2 by respiration (inefficient ventilation).\n\nA negative change from baseline indicates less symptom severity.", "populationDescription": "Full Analysis Set including patients with a valid measurements for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "no units", "timeFrame": "Baseline, 6 weeks, 3 months", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "OG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "6 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "87"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "spread": "0.597"}, {"groupId": "OG001", "value": "0.18", "spread": "0.629"}]}]}, {"title": "3 months", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "83"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.76", "spread": "0.542"}, {"groupId": "OG001", "value": "-0.07", "spread": "0.575"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "6 weeks", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1678", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "-1.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.98", "ciUpperLimit": "0.52", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.888"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "3 months", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3052", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.77", "ciUpperLimit": "2.43", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.809"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Exercise Capacity (Watt) at Ventilatory Anaerobic Threshold (VAT)", "description": "Cardiopulmonary exercise testing (CPET) is an established method to evaluate the exercise tolerance of heart failure patients by evaluating the cardio-pulmonary system using the measurement of respiratory gases during physical (exercise) stress. CPET was performed at a cycle ergometer with a workload that started at 10 watts (W) and then increased by 10W for each 1-minute stage.\n\nExercise capacity assessed as workload in watts was determined at the ventilatory anaerobic threshold (VAT) which represents the transition from aerobic to partially anaerobic glucose metabolism in muscle, leading to increasing carbon dioxide exhalation in comparison to oxygen uptake.\n\nA positive change from baseline in exercise capacity (watt) indicates improvement.", "populationDescription": "Full Analysis Set including patients with a valid measurements for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Watt", "timeFrame": "Baseline, 6 weeks, 3 months", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "OG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "6 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "82"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.71", "spread": "1.168"}, {"groupId": "OG001", "value": "0.83", "spread": "1.234"}]}]}, {"title": "3 months", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "79"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.45", "spread": "1.436"}, {"groupId": "OG001", "value": "-0.83", "spread": "1.483"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "6 weeks", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6181", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.58", "ciUpperLimit": "4.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.744"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "3 months", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1254", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "3.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.93", "ciUpperLimit": "7.48", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.124"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Rate of Perceived Exertion (Perceived Dyspnea and Perceived Fatigue) During Exercise Assessed by Borg Scale", "description": "The individually perceived exertion, in terms of perceived dyspnea and perceived fatigue, during cardiopulmonary exercise testing (CPET) was assessed by Borg scale which is a 15 point scale, starting from 6 which indicates \"No exertion at all\" to 20 which means \"Maximal exertion\".\n\nChange in Borg scale for both perceived dyspnea and perceived fatigue were measured at different time points at Baseline (Visit 2, 9 days prior randomization) and 3 months of treatment (Visit 7). Maximum value among the time points at every visit was used for the analysis.\n\nA negative change from baseline in Borg value of perceived dyspnea and perceived fatigue indicates improvement.", "populationDescription": "Full Analysis Set including patients with a valid measurements for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on scale", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks."}, {"id": "OG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Borg value perceived dyspnea", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "85"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "0.212"}, {"groupId": "OG001", "value": "0.11", "spread": "0.223"}]}]}, {"title": "Borg value perceived fatigue", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "85"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "0.167"}, {"groupId": "OG001", "value": "-0.20", "spread": "0.178"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Borg value dyspnea", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3432", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "-0.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.93", "ciUpperLimit": "0.33", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.317"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Borg value fatigue", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5319", "statisticalMethod": "ANCOVA", "paramType": "LS Mean", "paramValue": "0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.34", "ciUpperLimit": "0.65", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.251"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days (16 weeks on average).", "description": "Any signs or symptoms that occurs during study treatment plus the 30 days post treatment.", "eventGroups": [{"id": "EG000", "title": "LCZ696", "description": "LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.", "deathsNumAffected": 2, "deathsNumAtRisk": 103, "seriousNumAffected": 12, "seriousNumAtRisk": 103, "otherNumAffected": 52, "otherNumAtRisk": 103}, {"id": "EG001", "title": "Enalapril", "description": "Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.\n\nPatients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.", "deathsNumAffected": 1, "deathsNumAtRisk": 98, "seriousNumAffected": 14, "seriousNumAtRisk": 98, "otherNumAffected": 36, "otherNumAtRisk": 98}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Aortic valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Atrial tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Atrial thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 98}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Vascular stent occlusion", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Gastroenteritis norovirus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Angiocardiogram", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "International normalised ratio abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}, {"term": "Glioblastoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 98}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 98}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 98}]}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 98}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 98}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 98}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 98}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 98}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 98}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 98}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "Novartis.email@@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-07-24", "uploadDate": "2020-09-16T05:32", "filename": "Prot_000.pdf", "size": 695847}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-02-10", "uploadDate": "2020-09-16T05:32", "filename": "SAP_001.pdf", "size": 803510}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27579", "name": "Heart Failure, Systolic", "relevance": "LOW"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000004656", "term": "Enalapril"}, {"id": "D000015773", "term": "Enalaprilat"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Allopurinol", "relevance": "HIGH"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M7822", "name": "Enalapril", "asFound": "Transmission", "relevance": "HIGH"}, {"id": "M18330", "name": "Enalaprilat", "asFound": "Transmission", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}